TriMas Corp. (NASDAQ:TRS) reported second quarter adjusted EPS of $0.30 Tuesday morning, down from $0.37 a year ago. Analysts expected EPS of $0.31. Full year adjusted EPS is expected to be between $1.15 and $1.25. The consensus estimate is for EPS of $1.43. TriMas gapped open lower Tuesday and has fallen sharply in early trade. Shares are now down 3.46 at $19.30 on above average volume. The stock has plunged to a new low for the year. TriMas Corporation (NASDAQ:TRS) belongs to Industrial Goods sector. Its net profit margin is 5.50% and weekly performance is -17.83%. On last trading day company shares ended up $18.59. TriMas Corporation (NASDAQ:TRS) distance from 50-day simple moving average (SMA50) is -22.02%.
Zacks downgraded shares of Cloud Peak Energy Inc. (NYSE:CLD) from a buy rating to a hold rating. Cloud Peak Energy Inc. (NYSE:CLD) shares fell -8.59% in last trading session and ended the day at $2.66. CLD Gross Margin is 16.60% and its return on assets is 1.90%. Cloud Peak Energy Inc. (NYSE:CLD) quarterly performance is -63.16%.
It was reported on 16 July, that Blonder Tongue Laboratories, Inc. (NYSEMKT:BDR) was saddened to report the passing of one of the company’s founders, Ben H. Tongue, who died in his sleep early the morning of July 4, 2015. On 04 August, Blonder Tongue Laboratories Inc. (NYSEMKT:BDR) shares advanced 1.22% and was closed at $0.83. BDR EPS growth in last 5 year was -69.50%. Blonder Tongue Laboratories Inc. (NYSEMKT:BDR) year to date (YTD) performance is -69.14%.
Trovagene, Inc. (NASDAQ:TROV) recently declared the pricing of an underwritten public offering of 4,000,000 shares of its common stock. The gross proceeds to Trovagene from this offering are predictable to be $35 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene.TrovaGene, Inc. (NASDAQ:TROV) ended the last trading day at $7.50. Company weekly volatility is calculated as 6.89% and price to cash ratio as 5.04. TrovaGene, Inc. (NASDAQ:TROV) showed a weekly performance of -10.18%.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has submitted its New Drug Application (NDA) regulatory filing to the U.S. Food and Drug Administration (FDA) for rociletinib for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation as detected by an FDA approved test. Rociletinib is the Company’s novel, oral targeted covalent (irreversible) mutant-selective inhibitor of EGFR in development for the treatment of NSCLC in patients with initial activating EGFR mutations, as well as the dominant resistance mutation T790M. Rociletinib was granted Breakthrough Therapy designation by the U.S. FDA in May 2014. Clovis Oncology, Inc. (NASDAQ:CLVS) shares advanced 1.40% in last trading session and ended the day at $86.85. CLVS return on assets is -26.30%. Clovis Oncology, Inc. (NASDAQ:CLVS) quarterly performance is 8.94%.